

Amendment to the Specification:

Amendment is made to the Specification paragraphs indicated below.

[0017] Hydroxyalkylquinoline compounds can be used for the relief of symptoms due to active viral infections. In particular, the active ingredient of Singulair® medication can relieve blisters and skin lesions such as 1) skin lesions on the face, lip and oral mucosa overlying soft tissue due to an active Herpes Simplex I infection (HSV-I); 2) skin lesions on the genitals and anus due to an active Herpes Simplex I (HSV-I) infection or Herpes Simplex II infection (HSV-II); and 3) variously located skin lesions due to an active infection of Herpes zoster (chicken pox virus). The standard oral dose of about 4 to about 10 milligrams is appropriate for the treatment of existing blisters in a patient.

[0032] A carpenter who was experiencing the symptoms of carpal tunnel syndrome was treated with 10 mg of Singulair® medication per day, taken orally, for four weeks. He continued to perform his daily occupational activities throughout the period of treatment. He obtained complete remission of symptoms. Following cessation of treatment, the symptoms recurred. Patient was then treated for short courses of 10 mg of Singulair® medication per day, whenever symptoms were present, until symptoms subsided.

[0033] A patient who worked as a billing clerk had carpal tunnel symptoms which had not responded to non-surgical methods of treatment. Patient was treated with Singulair® medication at 10 mg daily, taken orally. After six weeks, she experienced complete resolution of her carpal tunnel symptoms. Though she continued her occupational activities as a billing clerk, after forty weeks, she remained symptom-free.

[0034] A patient who works as a data entry clerk, experienced severe carpal tunnel symptoms. She ceased her occupational activities and began treatment with Singulair® medication at 10 mg per day, taken orally. After four weeks of therapy, her symptoms had completely resolved, and she returned to work, continuing the Singulair® medication treatment. Upon recheck in two

weeks, she remained symptom-free. At this time, treatment with Singulair® medication was discontinued, and patient remained symptom-free thereafter.

[0035] Patient was an insurance clerk who experienced severe carpal tunnel symptoms which had not abated, even after carpal tunnel decompression surgery. For years following surgery, she had experienced severe carpal tunnel symptoms. After six weeks of therapy with Singulair® medication at 10 mg per day taken orally, she experienced complete resolution of her symptoms, despite the fact that she continued routine occupational activities. When treatment was stopped, her symptoms rapidly returned. Symptoms abated with resumption of treatment, and with continuing treatment, she remains symptom-free.

[0036] Patient was an assembly line worker at an automobile production facility who was experiencing symptoms of carpal tunnel syndrome was treated with 10 mg of Singulair® medication per day taken orally. He continued to perform his daily occupational activities and noted that his symptoms abated after six weeks of treatment. He required continuous treatment with 10 mg of Singulair® medication per day taken orally to maintain remission of his symptoms.

[0037] Patient was a golfer who experienced symptoms of cubital tunnel syndrome. Lengthy treatments with multiple non-steroidal anti-inflammatory drugs, cessation of the causative activity (golf), and use of elbow splints failed to relieve patient's symptoms. Patient was treated with Singulair® medication at 10 mg daily, taken orally. Symptoms were entirely abated after four weeks. No further treatment was required despite his return to his regular golfing activity.

[0038] Patient exhibited symptoms of thoracic outlet syndrome including a pain radiating down the left arm, a burning sensation beneath the left scapula, weakness of the left hand, and intermittent numbness of the left hand. Patient was treated with Singulair® medication at 10 mg per day taken orally. After four weeks, symptoms had completely resolved. No further treatment was required.

[0040] Patient had recently discontinued use of Singulair® medication as a treatment for asthma. Five days later, patient developed a cold sore, possibly caused by excessive exposure to ultraviolet light. The cold sore resolved in three days after treatment with Singulair® medication was resumed.[[-]] The rate of resolution was faster than the resolution of previous sores which were treated with antiviral treatments such as those marketed under the trademarks Zovirax® or Famvir® (approximately seven to ten days). During the subsequent two years, patient took Singulair® medication on a daily basis (10 mg, twice a day). In that time period, patient was exposed to levels of ultraviolet light which were as high as those which had possibly induced the sore, yet no new sore developed.

[0041] A patient who had a history of developing an average of two cold sores per month was treated with Singulair® medication at 10 mg per day, taken orally. No cold sore was present at the time therapy was started. Patient remained free of cold sores with continuous daily treatment for ten months. Within five days of termination of treatment, a cold sore developed. The patient restarted treatment, and remained free of cold sores as of thirteen months after resumption of treatment.

[0042] Patient had post-herpetic neuralgia due to a latent Herpes infection. Neuralgia developed despite initial treatment with anti-viral agents as per standard treatment recommendations. Patient began treatment with Singulair® medication (10 mg per day, taken orally). The post-herpetic neuralgia resolved in ten days. No further treatment was required.

[0043] Patient had postherpetic neuralgia due to a latent *Herpes* infection. Neuralgia developed despite initial treatment with anti-viral agents as per standard treatment recommendations. Patient began treatment with Singulair® medication (10 mg per day, taken orally). The post-herpetic neuralgia resolved in 14 days. No further treatment was required.

[0045] Patient had noted the onset of graying of the temple regions of his hair. No progression of the graying process in the temple region or development of graying in any other scalp areas

noted after two years and four months of continuous treatment with Singulair® medication (10 mg per day, taken orally).